Positive phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine

Positive results from the phase 1/2 dose-finding study evaluating the safety, pharmacokinetics and clinical activity of rilzabrutinib, an investigational oral Bruton